focus -WSS

focus

author：fashion 2025-08-25 16:35:03 - browse：6

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.

For more on what we cover, here’s all of Rachel’s coverage; here’s more on Vertex’s competition; here’s the news on Gilead; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Chinese researcher claims birth of first gene

hotspot

WSS

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Republican states more likely to report Covid vaccine side effects

Pregnancy ages women, but effects reverse after delivery

Testing GLP

Bring on the sabbaticals for nurses

Overprescribed: High cost isn't America's only drug problem

focus

focus

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Diabetes management: Digital health tools fall short, study says

Novavax promises a turnaround & Lilly roils the obesity market

Scientific mystery highlights the blind spots in genomics databases

In Memoriam: Notable people who died in 2023

Pfizer, Moderna say biotech, pharma drug development is a sprint

BioMarin wins approval for gene therapy to treat hemophilia A

Steward Health Care expansion into Malta flopped

DIEP, the 'gold standard' of breast reconstruction, is under threat

Scientific mystery highlights the blind spots in genomics databases

knowledge

Pregnancy ages women, but effects reverse after delivery

Pregnancy ages women, but effects reverse after delivery

People with mental disorders often marry others with same

This gene therapy has record $4.25 million price. It's saved children.

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

First Opinion on colorectal cancer screening: letter and response

hotspot

hotspot

focus

focus